<SEC-DOCUMENT>0001367644-14-000002.txt : 20140113
<SEC-HEADER>0001367644-14-000002.hdr.sgml : 20140113
<ACCEPTANCE-DATETIME>20140113073306
ACCESSION NUMBER:		0001367644-14-000002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140113
DATE AS OF CHANGE:		20140113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		14523209

	BUSINESS ADDRESS:	
		STREET 1:		2273 RESEARCH BLVD, SUITE 400
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(301) 795-1800

	MAIL ADDRESS:	
		STREET 1:		2273 RESEARCH BLVD, SUITE 400
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Emergent
    Document created using Disclosure Solutions PROFILE 1.3.2.0
    Copyright 1995 - 2014 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 16pt; FONT-WEIGHT: bold">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 12pt; FONT-WEIGHT: bold"><font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 16pt">SECURITIES AND EXCHANGE COMMISSION</font><font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 12pt"><br>
</font> WASHINGTON, D.C. 20549</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">____________________</div>

<div style="TEXT-ALIGN: center; MARGIN-TOP: 12pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 18pt; FONT-WEIGHT: bold">FORM 8-K</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">CURRENT REPORT<font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 12pt"><br>
</font> Pursuant to Section 13 or 15(d) of the</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Securities Exchange Act of 1934</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">Date of report (Date of earliest event reported):&#160;&#160;<font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">January 13, 2014</font></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Emergent BioSolutions Inc.</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">(Exact Name of Registrant as Specified in Charter)</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 34.96%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Delaware</div>
</td>
<td style="WIDTH: 30.08%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">001-33137</div>
</td>
<td style="WIDTH: 34.96%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">14-1902018</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.96%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt">(State or Other Jurisdiction</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt">of Incorporation)</div>
</td>
<td style="WIDTH: 30.08%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt">(Commission<font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt"><br>
</font> File Number)</div>
</td>
<td style="WIDTH: 34.96%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt">(IRS Employer<font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt"><br>
</font> Identification No.)</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 12pt"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 65.04%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">2273 Research Boulevard, Suite 400, Rockville, Maryland</div>
</td>
<td style="WIDTH: 34.96%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">20850</div>
</td>
</tr>

<tr>
<td style="WIDTH: 65.04%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt">(Address of Principal Executive Offices)</div>
</td>
<td style="WIDTH: 34.96%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt">(Zip Code)</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">Registrant's telephone number, including area code: &#160;<font style="FONT-FAMILY: 'Times New Roman', serif; FONT-SIZE: 11pt; FONT-WEIGHT: bold">(301) 795-1800</font></div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 3pt; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Not applicable</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">(Former Name or Former Address, if Changed Since Last Report)</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">&#61551; Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">&#61551; Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">&#61551; Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman', serif; MARGIN-BOTTOM: 12pt; FONT-SIZE: 11pt">&#61551; Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<hr style="PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000; CLEAR: both" id="DSPFPageBreak" noshade="noshade">
</div>

<div><br>
</div>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Item 2.02. Results of Operations and Financial Condition.</div>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt">On January 13, 2014, Emergent BioSolutions Inc. announced preliminary unaudited financial results for 2013 and guidance for 2014. The full text of the press release issued in connection with the announcement is attached as Exhibit 99 to this Current Report on Form 8-K.</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Calibri, sans-serif; FONT-SIZE: 11pt">&#160;</div>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; FONT-WEIGHT: bold">Item 9.01. Financial Statements and Exhibits.</div>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt"><br>
</div>

<div style="TEXT-ALIGN: left; TEXT-INDENT: 36pt; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt">(d) Exhibits</div>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: middle" colspan="3">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.22%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: middle">
<div>&#160;</div>
</td>
<td style="WIDTH: 0.9%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: middle">
<div>&#160;</div>
</td>
<td style="WIDTH: 89.88%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: middle">
<div>&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 9.22%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center; FONT-WEIGHT: bold">Number</div>
</td>
<td style="WIDTH: 0.9%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="BORDER-BOTTOM: #000000 2px solid; WIDTH: 89.88%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: center; FONT-WEIGHT: bold">Exhibit</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.22%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: center">99</div>
</td>
<td style="WIDTH: 0.9%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: bottom">
<div>&#160;</div>
</td>
<td style="WIDTH: 89.88%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: bottom">
<div style="TEXT-ALIGN: left; FONT-SIZE: 11pt">Press release issued by the company on January 13, 2014.</div>
</td>
</tr>
</table>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt"><br>
</div>

<div style="MARGIN-TOP: 10pt; FONT-FAMILY: 'Times New Roman'; MARGIN-BOTTOM: 10pt; CLEAR: both; FONT-SIZE: 11pt" id="DSPFPageBreakArea">
<hr style="PAGE-BREAK-AFTER: always; MARGIN: 4px 0px; WIDTH: 100%; HEIGHT: 2px; COLOR: #000000; CLEAR: both" id="DSPFPageBreak" noshade="noshade">
</div>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt">&#160;</div>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt"><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; FONT-WEIGHT: bold">SIGNATURE</div>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt"><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt"><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 20px">
<td style="WIDTH: 49.87%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left">Date:&#160;&#160;January 13, 2014</div>
</td>
<td style="WIDTH: 50.13%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: top" colspan="2">
<div style="TEXT-ALIGN: left">EMERGENT BIOSOLUTIONS INC.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 49.87%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: top">
<div>&#160;</div>
</td>
<td style="WIDTH: 5.88%; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: right">By:</div>
</td>
<td style="BORDER-BOTTOM-COLOR: ; WIDTH: 44.25%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt">/<u>s/ A.B. Cruz</u></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt">A.B.Cruz III</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 11pt">Executive Vice President and General Counsel</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Calibri, sans-serif; COLOR: #1f497d; FONT-SIZE: 11pt">&#160;</div>
</td>
</tr>
</table>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>

<div><br>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit99.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Emergent
    Document created using Disclosure Solutions PROFILE 1.3.2.0
    Copyright 1995 - 2014 Thomson Reuters Accelus.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<div><br>
 &#160;</div>

<div><br>
</div>

<div style="TEXT-ALIGN: right; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 99</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2013 FINANCIAL RESULTS AND PROVIDES 2014 FORECAST</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ROCKVILLE, Maryland</font>&#8212;<font style="FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">January 13, 2014</font>&#8212;Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary 2013 financial results and provided guidance for 2014.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Preliminary 2013 Results</u></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">For full year 2013, the company anticipates total revenues of $311 to $313 million, which includes approximately $258 million of product sales and $53 to $55 million of contracts and grants revenue. &#160;The product sales comprise approximately $247 million of BioThrax revenue and approximately $11 million of RSDL revenue. &#160;The company also anticipates full year 2013 GAAP net income of $30 to $32 million. &#160;Excluding approximately $7 million of transaction-related and restructuring costs incurred during the year, the company is providing a forecast for 2013 non-GAAP adjusted net income of $35 to $37 million (see "Non-GAAP Financial Measures" for a definition of terms and a reconciliation of Non-GAAP adjusted net income to GAAP net income). &#160;In addition, the company ended 2013 with cash and cash equivalents of approximately $180 million and an account receivable balance of approximately $60 million.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>2014 Forecast</u></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">For full year 2014, and assuming a late Q1 close of the Cangene acquisition, the company forecasts total revenues of $415 to $445 million. &#160;This consists of $260 to $280 million of product sales, $55 to $65 million of contracts and grants revenue, plus approximately $100 million in anticipated revenue contribution from Cangene. &#160;The company also forecasts full year 2014 GAAP net income of $30 to $40 million.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Daniel J. Abdun-Nabi, president and chief executive officer of Emergent BioSolutions Inc., stated, "Our performance in 2013 reflects continued strength in our base biodefense business, which was expanded and diversified in the year through the successful acquisition of RSDL and the additional revenue that came with that highly complementary transaction. &#160;During 2014, we will be focused on continuing to implement the objectives outlined in our growth plan, including executing on our M&amp;A strategy and defraying our R&amp;D costs through commercial partnerships and government funding, as we advance toward meeting and potentially exceeding our long term growth goals."</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">The preliminary 2013 financial results are subject to revision and will be finalized upon the completion of the company's external audit, which is anticipated in early March 2014. &#160;Once the external audit is completed, the company may report financial results that could differ, and the differences could be material.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Non-GAAP Financial Measures</u></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">This press release contains a financial measure, adjusted net income, which is considered a "non-GAAP" financial measure under applicable Securities &amp; Exchange Commission rules and regulations. &#160;This non-GAAP financial measure should be considered supplemental to and not a substitute for financial information prepared in accordance with generally accepted accounting principles. &#160;The company's definition of this non-GAAP measure may differ from similarly titled measures used by others. &#160;The non-GAAP financial measure used in this press release adjusts for specified items that can be highly variable or difficult to predict. &#160;The company views this non-GAAP financial measure as a means to facilitate management's financial and operational decision-making, including evaluation of the company's historical operating results and comparison to competitors' operating results. &#160;This non-GAAP financial measure reflects an additional way of viewing aspects of the company's operations that, when viewed with GAAP results and the reconciliations to the corresponding GAAP financial measure, may provide a more complete understanding of factors and trends affecting the company's business.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">The determination of the amounts that are excluded from this non-GAAP financial measure is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts. &#160;The company is likely to exclude the following items from its non-GAAP adjusted net income in the future, the effect of which is uncertain but may be significant in amount:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">&#160;</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Symbol, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Expenses related to completed and future acquisitions of other businesses, including amortization of acquired intangible and tangible assets, and transaction costs;</div>
</td>
</tr>
</table>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Symbol, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Expenses associated with any potential restructuring activities, including but not limited to, asset impairments, accelerated depreciation, severance costs and lease abandonment charges; and</div>
</td>
</tr>
</table>
</div>

<div>
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" class="DSPFListTable" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Symbol, serif; MARGIN-LEFT: 18pt; FONT-SIZE: 10pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Other one-time or non-recurring charges.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Because non-GAAP financial measures exclude the effect of items that will increase or decrease the company's reported results of operations, management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. &#160;A reconciliation of the non-GAAP financial measure to the most directly comparable GAAP financial measure is included in the following table.</div>

<div><br>
</div>

<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0">
<tr style="BACKGROUND-COLOR: #0f243e">
<td style="BORDER-BOTTOM: #ffffff 4px double; WIDTH: 49.8%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; FONT-STYLE: italic; FONT-FAMILY: Verdana, sans-serif; COLOR: #ffffff; FONT-SIZE: 10pt">(in millions)</div>
</td>
<td style="BORDER-BOTTOM: #ffffff 4px double; WIDTH: 50.2%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; COLOR: #ffffff; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Preliminary Financial Results for the Year Ended December 31, 2013</div>
</td>
</tr>

<tr style="BACKGROUND-COLOR: #bfbfbf">
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 49.8%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GAAP Net Income</div>
</td>
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 50.2%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$30 to $32</div>
</td>
</tr>

<tr style="BACKGROUND-COLOR: #d9d9d9">
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 49.8%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Adjustments:</div>
</td>
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 50.2%; VERTICAL-ALIGN: middle">
<div>&#160;</div>
</td>
</tr>

<tr style="BACKGROUND-COLOR: #bfbfbf">
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 49.8%; VERTICAL-ALIGN: middle">
<div><font style="FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt">&#183;</font><font style="FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Cangene transaction-related costs</font></div>
</td>
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 50.2%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">3.3</div>
</td>
</tr>

<tr style="BACKGROUND-COLOR: #d9d9d9">
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 49.8%; VERTICAL-ALIGN: middle">
<div><font style="FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt">&#183;</font><font style="FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">HPPD transaction-related costs</font></div>
</td>
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 50.2%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">0.8</div>
</td>
</tr>

<tr style="BACKGROUND-COLOR: #bfbfbf">
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 49.8%; VERTICAL-ALIGN: middle">
<div><font style="FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt">&#183;</font><font style="FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">UK restructuring expense</font></div>
</td>
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 50.2%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">2.8</div>
</td>
</tr>

<tr style="BACKGROUND-COLOR: #d9d9d9">
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 49.8%; VERTICAL-ALIGN: middle">
<div><font style="FONT-FAMILY: Symbol, serif; FONT-SIZE: 10pt">&#183;</font><font style="FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Tax effect of non-GAAP adjustments</font></div>
</td>
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 50.2%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">(2.0)</div>
</td>
</tr>

<tr style="BACKGROUND-COLOR: #bfbfbf">
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 49.8%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Non-GAAP Adjusted Net Income</div>
</td>
<td style="BORDER-BOTTOM: #ffffff 2px solid; WIDTH: 50.2%; VERTICAL-ALIGN: middle">
<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">$35 to $37</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>About Emergent BioSolutions Inc.</u></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. &#160;Additional information about the company may be found at <font style="FONT-FAMILY: Verdana, sans-serif; COLOR: #0000ff; FONT-SIZE: 10pt"><u>www.emergentbiosolutions.com</u></font>.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Follow us on twitter: <font style="FONT-FAMILY: Verdana, sans-serif; COLOR: #0000ff; FONT-SIZE: 10pt"><u>@emergentbiosolu</u></font></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><u>Emergent BioSolutions Safe Harbor Statement</u></div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the expected closing of the Cangene transaction, the potential opportunities and financial impact of the transaction, our financial guidance, and any other statements containing the words "believes", "expects", "anticipates", "intends", "plans", "forecasts", "estimates" and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development, regulatory approvals or expenditures are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including uncertainties as to the satisfaction of closing conditions with respect to the Cangene transaction, including the timing and receipt of Cangene shareholder, Canadian court<font style="FONT-FAMILY: 'Times New Roman', serif; COLOR: #1f497d; FONT-SIZE: 12pt">&#160;</font>and regulatory approvals; our ability to successfully integrate the business and realize the potential benefits of the transaction; appropriations for BioThrax<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> procurement; our ability to successfully integrate the recent acquisition of the HPPD business and realize the benefits of the HPPD transaction; our ability to obtain new BioThrax sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax; availability of funding for our U.S. government grants and contracts; our ability to identify and acquire or in-license products or late-stage product candidates that satisfy our selection criteria; whether anticipated synergies and benefits from an acquisition or in-license are realized within expected time periods or at all; our ability to enter into selective collaboration arrangements; our ability to expand our manufacturing facilities and capabilities; our ability to meet operating and financial restrictions placed on us and our subsidiaries that are contained in our senior credit facility; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization, marketing and manufacturing capabilities and strategy. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements.</div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">###</div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Emergent BioSolutions Investor Contact:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Robert G. Burrows</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Vice President, Investor Relations</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">301-795-1877</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; COLOR: #0000ff; FONT-SIZE: 10pt"><u>BurrowsR@ebsi.com</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Emergent BioSolutions Media Contact:</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Tracey Schmitt</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">Vice President, Corporate Communications</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 10pt">301-795-1800</div>

<div style="TEXT-ALIGN: left; FONT-FAMILY: Verdana, sans-serif; COLOR: #0000ff; FONT-SIZE: 10pt"><u>SchmittT@ebsi.com</u></div>

<div><br>
</div>

<div style="TEXT-ALIGN: center; FONT-FAMILY: Verdana, sans-serif; FONT-SIZE: 9pt"></div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
